Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Oncology Institute (TOI) Other financing activities (2020)

Oncology Institute's Other financing activities history spans 1 years, with the latest figure at -$3.8 million for Q4 2020.

For Q4 2020, Other financing activities changed N/A year-over-year to -$3.8 million; the TTM value through Dec 2023 reached -$3.8 million, down 0.94%, while the annual FY2022 figure was $3.7 million, N/A changed from the prior year.
Other financing activities reached -$3.8 million in Q4 2020 per TOI's latest filing, down from $35122.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $10.4 million in Q1 2020 to a low of -$3.8 million in Q4 2020.